Goldman Sachs
MLNT

Goldman Sachs’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Goldman Sachs’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-212
Closed -$17K – 6579
2017
Q4 		$17K Buy
+212
New +$15.7K ﹤0.01% 6141

Other funds holding MLNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Goldman Sachs's MLNT Position: Q3 2019 in Review

Goldman Sachs sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 12,650 shares — an estimated $84K sold.

Goldman Sachs first reported a position in MLNT in Q4 2017 and held it in 4 quarters. The position peaked at $490K in Q4 2017. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

  • Goldman Sachs reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Goldman Sachs sold 12,650 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $84K.
  • Goldman Sachs first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Goldman Sachs's Melinta Therapeutics, Inc. Common Stock position peaked at $490K in Q4 2017.
  • 47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.